A Study of IBI3046 in Participants With Overweight or Obesity

Other illness

• 1\. Secondary overweight or obesity caused by drugs, genetic or other systemic diseases.
• 5\. Personal or family history of specific thyroid neoplasms or endocrine disorders, or clinically significant abnormal thyroid function and thyroid lesions at screening.
• 6\. History of pancreatitis, severe lipid metabolism disorders, severe hypoglycemia or diabetic ketoacidosis.
• 7\. Presence of untreated or clinically significant systemic organ diseases, mental disorders or suicidal risk.
• 8\. History of malignant tumors (excluding partial skin cancers) within 5 years.
• 10\. Personal or family history of specific thyroid neoplasms or endocrine disorders, or clinically significant abnormal thyroid function and thyroid lesions at screening.
• 11\. History of pancreatitis, severe lipid metabolism disorders, severe hypoglycemia or diabetic ketoacidosis.
• 12\. Presence of untreated or clinically significant systemic organ diseases, mental disorders or suicidal risk.
• 13\. History of malignant tumors (excluding partial skin cancers) within 5 years.

Lab values

• 2\. Abnormal glucose metabolism, including diabetes history or clinically significant abnormal glycemic indicators at screening.

Other

• 3\. Clinically significant abnormal liver function, hematological parameters, ECG indicators or vital signs at screening.
• 4\. Positive screening results for infectious pathogen markers.
• 9\. Positive screening results for infectious pathogen markers.

• 1.Aged between 18 and 65 years (inclusive) at the time of informed consent, male or female;
• 2.At screening, 24 kg/m² ≤ BMI ≤ 40 kg/m²;
• 3.Body weight change ≤ 5 % within 3 months prior to screening ;
• 4.Female participants of child bearing potential and male participants whose partners are of child bearing potential must agree to use highly effective contraceptive methods during the study and for 6 months after the last study drug administration. For female participants of child bearing potential, the pregnancy test result must be negative at screening. Female participants shall not breast feed. Male / female participants must be willing to refrain from sperm / oocyte donation during the study and for 6 months after the last study drug administration;
• 5.Able to understand study procedures and requirements, willing to strictly comply with the clinical trial protocol, and voluntarily sign the informed consent form.